Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis
Andrew Blauvelt
(1)
,
Henrique Teixeira
(2)
,
Eric Simpson
(3)
,
Antonio Costanzo
(4)
,
Marjolein de Bruin-Weller
(5)
,
Sébastien Barbarot
(6, 7)
,
Vimal Prajapati
(8)
,
Peter Lio
(9)
,
Xiaofei Hu
(2)
,
Tianshuang Wu
(2)
,
John Liu
(2)
,
Barry Ladizinski
(2)
,
Alvina Chu
(2)
,
Kilian Eyerich
(10)
1
Oregon Medical Research Center
2 Abbvie Inc. [North Chicago]
3 OHSU - Oregon Health and Science University [Portland]
4 Hunimed - Humanitas University [Milan]
5 University Medical Center [Utrecht]
6 PhAN - Physiopathologie des Adaptations Nutritionnelles
7 CHU Nantes - Centre Hospitalier Universitaire de Nantes
8 University of Calgary
9 Northwestern University [Chicago, Ill. USA]
10 TUM - Technische Universität Munchen - Technical University Munich - Université Technique de Munich
2 Abbvie Inc. [North Chicago]
3 OHSU - Oregon Health and Science University [Portland]
4 Hunimed - Humanitas University [Milan]
5 University Medical Center [Utrecht]
6 PhAN - Physiopathologie des Adaptations Nutritionnelles
7 CHU Nantes - Centre Hospitalier Universitaire de Nantes
8 University of Calgary
9 Northwestern University [Chicago, Ill. USA]
10 TUM - Technische Universität Munchen - Technical University Munich - Université Technique de Munich